Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.13263 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Byungwook Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Uremia, Dipeptidyl-Peptidase IV Inhibitors, Models, Biological, Piperazines. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dong-A ST Co., Ltd..
Abstract (Originalsprache)
Uremia, a condition characterized by the retention of uremic toxins due to impaired renal function, may affect drug metabolism mediated by CYP3A4 enzymes. Evogliptin is a dipeptidyl peptidase‐4 (DPP‐4) inhibitor diabetic drug that is primarily metabolized by CYP3A4. This study aimed to construct a population pharmacokinetic (PK) and pharmacodynamic (PD) model for evogliptin in patients with varying degrees of renal disease, including end‐stage renal disease on hemodialysis. A total of 688 evogliptin concentration and 598 DPP‐4 activity data were available from 46 subjects. PK and PD data analyses were performed using a nonlinear mixed‐effects model. The PK of evogliptin was optimally described by a two‐compartment model with first‐order absorption. The significant covariates in the final model included blood amylase and triglyceride on F1 (relative bioavailability). The simulation findings, together with previously reported PK data, provided evidence of a significant inhibition of the first‐pass effect of evogliptin in patients with renal impairment. A direct link sigmoidal E max model was developed to describe the relationship between evogliptin concentration and DPP‐4 inhibition. The PD model predicted significant inhibition of DPP‐4 at maximum effect ( E max : 88.9%) and a low EC 50 value (1.08 μg/L), indicating the high potency and efficacy of evogliptin. The developed PK/PD model accurately predicted exposure and the resulting DPP‐4 activity of evogliptin in renal impairment. The findings of this study suggest that renal impairment and associated biochemical changes may impact the bioavailability of CYP3A4‐metabolized drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
- College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
- Department of Pharmacology, Jeju National University College of Medicine, Jeju, Republic of Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea.
ORCID-Profile: Byungwook Kim, Jung Eun Kim, Soyoung Lee, Jaeseong Oh, Joo-Youn Cho, In-Jin Jang, SeungHwan Lee, Jae-Yong Chung, Seonghae Yoon
Förderung
- Dong-A ST Co., Ltd.
Zitieren
APA
Kim, B., Kim, J. E., Lee, S., Oh, J., Cho, J. Y., Jang, I. J., Lee, S., Chung, J. Y., & Yoon, S. (2025). Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13263
Vancouver
Kim B, Kim JE, Lee S, Oh J, Cho JY, Jang IJ, et al. Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13263
BibTeX
@article{Kim2025,
author = {Kim, Byungwook and Kim, Jung Eun and Lee, Soyoung and Oh, Jaeseong and Cho, Joo-Youn and Jang, In-Jin and Lee, SeungHwan and Chung, Jae-Yong and Yoon, Seonghae},
title = {Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.13263}
}
EUVIMED